It is an interesting target, but I'd be curious to know how it is differentiated from AMD3100 (Mozobil, plerixafor), which is an agent with this same MOA that is approved for use in stem cell mobilization and is also in a bunch of oncology trials.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.